FDA WARNS LILLY FOR ALIMTA MARKETING

Federal regulators asked pharmaceutical maker Eli Lilly and Co. to withdraw a "misleading" marketing brochure for its cancer drug Alimta. The Food and Drug Administration said the Indianapolis-based company published a 34-page patient brochure that "omits material facts and risk information essential to the safe and effective use" of the 2-year-old drug.
The News-Sentinel